Prolonged and symptomatic bradycardia following a single dose of fingolimod

Multiple Sclerosis Journal

Volumn 19, Issue 1, 2013, Pages 126-128

  Faber, Hans ^a   Fischer, Hans Jörg ^b   Weber, Frank ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Klinikum Schwabing   (Germany)

Author keywords

bradycardia; disease modifying therapies; fingolimod; multiple sclerosis

Indexed keywords

ATROPINE; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; CASE REPORT; CORONARY STENT; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FAMILY HISTORY; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; IMMUNOTHERAPY; ISCHEMIC HEART DISEASE; MALE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; RELAPSE; SINGLE DRUG DOSE; TREATMENT WITHDRAWAL; VAGOTOMY;

EID: 84872352059     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512447596     Document Type: Article

References (12)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
2. Kappos L, Radue EW, O'Connor P, et al. A placebo- controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
3. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant. 2005 ; 5: 529-536
4. DiMarco JP, O'Connor PW, Cohen JA, et al. First-dose effect of fingolimod: pooled safety data from two phase-3 studies (TRANSFORMS and FREEDOMS). Mult Scler. 2010 ; 16: S290
5. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002 ; 13: 1073-1083
6. European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya. Press release2012; http://www.ema.europa.eu
7. Lindsey J, Haden-Pinneri K, Memon N, Buja L. Sudden unexpected death on fingolimod. Mult Scler J. 2012 ;:
8. Espinosa PS, Berger. Delayed fingolimod-associated asystole. Mult Scler J. 2011 ; 17: 1387-1389
9. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Eur J Physiol. 1999 ; 438: 642-648
10. Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Cardiovascular effects and safety of fingolimod in clinical practice. 64th AAN Annual Meeting. 2012: P04 138
11. Kovarik JM, Slade A, Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol. 2008 ; 66: 199-206
12. Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006 ; 46: 895-904